Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

Impact · against what's priced in

The TECTONIC trial results provide a tangible catalyst for Abbott's medical devices growth, addressing the market's skepticism regarding the company's ability to sustain 10%+ revenue growth. While the product is not yet commercial, the high procedural success rate supports a future growth trajectory that the current valuation currently declines to pay for.

ABT+0.30

Challenges what's priced in

The price assumes